Larry Zhang - 24 Jul 2021 Form 4 Insider Report for CASI Pharmaceuticals, Inc.

Reporting relationship: President
Issuer ticker: N/A
Reported as of: 24 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jul 2021, 18:08:05 UTC
Source filing: View source filing
Reporting owner signature: /s/ Cynthia W. Hu, COO (US), Gen Counsel and Secretary

Filing notes and source

Key filing fact

Larry Zhang filed Form 4 for CASI Pharmaceuticals, Inc. on 26 Jul 2021.

Key facts

This page summarizes Larry Zhang's Form 4 filing for CASI Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jul 2021, 18:08.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CASI transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: -800,000
Change %: -50%
Price: $0.000000
Shares after: 800,000
Date: 24 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 800,000
Exercise price: $1.28
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option grant was approved by the Compensation Committee on July 24, 2021. The exercise price per share is the closing market price on July 23, 2021, the last trading day preceding the date of grant.

Footnote F2

The stock options will vest as follows: 25 percent on each of the first, second, third and fourth anniversaries of the date of grant.